Tech Company Financing Transactions
Scorpion Therapeutics Funding Round
Atlas Venture, Omega Funds and Vida Ventures participated in a $108 million Series A funding round for Scorpion Therapeutics. The round was announced by the company on 10/27/2020.
Transaction Overview
Company Name
Announced On
10/27/2020
Transaction Type
Venture Equity
Amount
$108,000,000
Round
Series A
Investors
Proceeds Purpose
The financing will be used to advance Precision Oncology 2.0., the next wave in precision medicine, with the goal of delivering small molecule drugs that are safe and well-tolerated and that can provide deeper, more durable responses to many more people with cancer.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
888 Boylston St. 1111
Boston, MA 02199
USA
Boston, MA 02199
USA
Phone
Website
Email Address
Overview
At Scorpion Therapeutics, we are working to expand the reach of precision medicine to more people with cancer, including cancers that are untreatable or treatment-resistant today. We are moving with equal parts urgency and rigor to change the status quo, drawing on our team's expertise and drive to accelerate our impact on patients.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Gary Glick
Chief Scientific Officer
Darrin Stuart
Executive Vice President
Erica Jackson
VP - Bus. Development
Lina Gugucheva
VP - General Counsel
Joseph Campisi
VP - Human Resources
Amanda Valentino
VP - Operations
Adam Friedman
Browse more venture capital transactions:
Prev: 10/27/2020: Grayshift venture capital transaction
Next: 10/28/2020: Caris Life Sciences venture capital transaction
Share this article
Where The Data Comes From
We record funding rounds that are announced publicly. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs